[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100270928":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":20,"studyPopulation":21,"armGroups":22,"interventions":11,"overallOfficials":25,"centralContacts":29,"locations":34,"responsibleParty":45,"collaborators":11,"id":47,"slug":11,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":11,"enrollmentInfo":55,"targetDuration":11,"studyType":58,"phases":11,"briefSummary":59,"conditions":60,"keywords":11,"overallStatus":36,"whyStopped":11,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"National Cancer Centre, Singapore","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"The molecular and clinical epidemiology for cancer patients being considered for novel therapeutics",null,"5 years",[14,16],{"measure":15,"description":11,"timeFrame":12},"The proportion of patients who have actionable alterations and enrol into clinical trials",{"measure":17,"description":11,"timeFrame":12},"The correlation of molecular profiles with clinical outcomes",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":19,"timePerspective":6,"maskingInfo":11},"COHORT","Molecular profiling will be performed on archival tumor tissue or freshly collected tumor tissue from re-biopsy. Blood, pleural fluid, FNA, and\u002For saliva may be collected to study the genetic makeup and also to compare the tumor molecular profile. Personalized therapy will be given based on molecular profile.","Any advanced cancer patient who would benefit from molecular profiling and is a potential clinical trial candidate as identified by treating physician.",[23],{"label":24,"type":11,"description":11,"interventionNames":11},"tumor tissue for molecular profiling",[26],{"name":27,"affiliation":5,"role":28},"Daniel SW Tan","PRINCIPAL_INVESTIGATOR",[30],{"name":27,"role":31,"phone":32,"phoneExt":11,"email":33},"CONTACT","+65 6436 8000","daniel.tan.s.w@singhealth.com.sg",[35],{"facility":5,"status":36,"city":37,"state":11,"zip":11,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":11},"RECRUITING","Singapore","SG",{"type":40,"coordinates":41},"Point",[42,43],103.85007,1.28967,{"lat":43,"lon":42},{"type":46,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100270928",false,"NCT02806388","Individualized Molecular Profiling for Allocation to Clinical Trials (IMPACT) Project","IMPACT","Inclusion Criteria:\n\n* Confirmed histological diagnosis of solid tumor\n* Suitable for systematic treatment and clinical trials\n* ECOG (Eastern cooperative oncology group) performance status \\\u003C 2\n* Able to provide tumor tissue for molecular profiling\n* Able to understand and sign the informed consent form\n\nExclusion Criteria:\n\n* None","ALL","12 Years",{"count":56,"type":57},5500,"ESTIMATED","OBSERVATIONAL","This study aims to screen tumor molecular profile for better selection of anticancer treatment, in particular, allocation to clinical trials if available.",[61],"Solid Tumor","2026-05-08",{"date":64,"type":65},"2026-05-13","ACTUAL",{"date":67,"type":11},"2011-10",{"date":69,"type":57},"2027-12-31",{"name":5,"class":6},1]